Nektar Therapeutics
Financials
Valuation Metrics
Nektar Therapeutics's Market Cap is $1.25B. At end of 2025 it was $858M. Ranked #2257 of 3,118 in US market (top 72%), #901 of 1,474 on NASDAQ (top 61%), #168 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.25B | US#2,257/3,118 Sec#168/265 |
| Revenue | $47M | US#2,746/3,118 Sec#148/265 |
| Net Income | $-157M | US—/3,118 Sec—/265 |
| Total Assets | $1.10B | US#2,425/3,118 Sec#97/265 |
| Net Assets | $903M | US#1,828/3,118 Sec#72/265 |
| Employees | 63 | US#2,671/3,118 Sec#197/265 |
| Value | ||
| P/B | 1.38x | US#865/3,118 Sec#37/265 |
| P/S | 26.35x | US#2,878/3,118 Sec#153/265 |
| FCF Yield | -18.75% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -17.40% | US#2,453/3,118 Sec#97/265 |
| ROA | -14.35% | US#2,728/3,118 Sec#116/265 |
| Op. Margin | -276.94% | US#2,757/3,118 Sec#141/265 |
| Revenue Growth | -36.77% | US#2,680/3,118 Sec#156/265 |
| Financial Health | ||
| Debt Ratio | 21.26% | US#240/3,118 Sec#81/265 |
| Total Debt | $136M | US#2,343/3,118 Sec#105/265 |
| FCF | $-234M | US#2,804/3,118 Sec#221/265 |
| Cash | $39M | US#2,673/3,118 Sec#236/265 |
| Current Ratio | 10.42x | US#232/3,118 Sec#74/265 |
| Performance | ||
| 1Y Return | -43.09% | US#2,703/3,118 Sec#218/265 |
| 1M Return | -15.21% | US#3,041/3,118 Sec#256/265 |
| From 52W High | -66.10% | US#2,901/3,118 Sec#231/265 |
| 1Y MDD | -64.34% | US#2,824/3,118 Sec#218/265 |
| Trading | ||
| Volume | 673,219 shares | US#2,141/3,118 Sec#210/265 |
| Trading Value | $25M | US#1,984/3,118 Sec#148/265 |
| Per Share | ||
| EPS | $-4.65 | US—/3,118 Sec—/265 |
| BPS | $26.73 | US#987/3,118 Sec#20/265 |
Company Info
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.